Institutional Sign In

Go

GlaxoSmithKline Czech Republic - Pre-Tax Profit Growth

GlaxoSmithKline CR`s Pre-Tax Profit Growth reached 66.5 % in 2017. This is 201 % less than in the previous year.

$1.99

Buy Pre-Tax Profit Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...           55.9 -37.5 9.53 30.0 -12.4    
Bayer Czech Republic % ... ... ...               27.9 -47.7 20.5 10.1 19.8    
GlaxoSmithKline Czech Republic % ... ... ...               32.4 -25.9 -23.1 -28.4 33.3    
Merck Czech Republic % ... ...                 208 20.3 -41.4 9.51 89.2    
Novartis Czech Republic %                     -1.98 -2.34 4.60 70.8 17.6    
Pfizer Czech Republic % ... ...                 132 -79.1 198 -6.94 -44.5    
Roche Czech Republic % ... ... ...               -39.1 -14.2 157 -26.8 -39.4   ...
Sanofi-Aventis Czech Republic % ... ... ... ...             51.8 -18.2 50.6 -98.0 5,393    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... 6.02 1.33 12.5    
Walmark % ... ... ...               44.2 -91.9 -108 -4,319 -1,273